ArticleJournal for immunotherapy of cancer2022

Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.

Christine M Minnar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.